Dyne.org, RIDDLE&CODE and InfoCert's Consortium Appointed to Take EBSI to the Next Level
21.9.2021 11:05:00 EEST | Business Wire | Press release
The consortium formed by Dyne.org, RIDDLE&CODE and InfoCert, has been selected by the European Commission as one of seven contractors to develop the next version of the European Blockchain Services Infrastructure (EBSI) .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005128/en/
The award is one more milestone in the consortium's track record of excellence with cryptography and blockchain, after Dyne.org led the flagship H2020 project DECODE, RIDDLE&CODE's blockchain solutions are deployed in banking and utility markets Europe wide and InfoCert being the largest Certification Authority at European level and eIDAS certified QTSP.
The European Commission's vision for EBSI is to leverage distributed ledger technologies to create international and intra-communautaire services for public administrations. The European Blockchain Partnership aims to scale the investment fund to a fully developed platform with up to €2 billion in funding.
The consortium led by the non-profit foundation Dyne.org is developing a multilayered network of blockchains for distributed secure execution of smart contracts, including edge-computing scenarios deployed on low-power embedded devices and chips. The blockchain-agnostic solution offers compatibility with a wide range of products to grant freedom of choice to participating member states and solution developers. Existing integrations include BigchainDB, Ethereum, Hyperledger Fabric, Hyperledger Sawtooth and Bitcoin.
Dyne.org's Zenroom is the core component of the solution. Its portable and secure smart-contract execution environment works standalone (zero dependency) even in a web browser. It can be programmed in a language similar to plain English and guarantees to be functional and portable for two decades to come. Dr. Francesca Bria, president of the Italian National Innovation Fund Cassa Depositi e Prestiti comments: "Zenroom stands for Citizen Crypto. It is a core part of the DECODE tech stack for Smart Cities and it makes it easy to understand the complexity of data transformation while being compatible with any platform, including Legacy Infrastructure. We make Crypto for Citizens and we make it Open Source."
Each member of this consortium gathers together a mature experience developing and deploying industrial standards, as well as facilitating open source community adoption of technologies, including the presence in major blockchain standardisation initiatives such as ISO TC/307, INATBA, W3C and Sovrin.
The combination of blockchain-specific hardware solutions for critical infrastructures, developed by RIDDLE&CODE, will help turn data sources into trusted ones and lay the foundation for EBSI's automated processes and scalability. The combination of InfoCert's leadership and scale when providing services for digital trust, security and identity management complying with standards will allow Europe to adopt mature blockchain solutions to mission-critical environments.
For the initial phase of EBSI's procurement, the consortium proposes a revolutionary solution for a European Digital Product Passport. As a path to success, the consortium plans to work actively to create an open "playing field" in Europe that can easily integrate a diversity of solutions and open this promising industrial field to new players from the public and private sectors.
Quote from the consortium members:
● Andrea D'Intino (EBSI Project leader, Dyne.org): "The consortium's unique combined understanding of cryptography, blockchain and identity technologies as well as its global market positioning, give us the tools and the strength to bring EBSI to the next level. We are truly excited to embrace the policy makers, the businesses and the developers into an inclusive community, to fuel their ideas and products into the European Union's blockchain."
● Thomas Fürstner (Founder & CTO, RIDDLE&CODE): "The blockchain landscape diversifies into layer one and layer two technologies. Layer one is used for attesting values and identities with a small transaction payload and low frequency. Layer two is used for high-volume, low-value, day-to-day transactions. Then, there is the neglected but important layer zero, where blockchain meets products and goods of the physical world. This is exactly where RIDDLE&CODE contributes to EBSI."
● Carmine Auletta (Chief Strategy and Innovation Officer, InfoCert - Tinexta Group): "Being involved in shaping the future EU blockchain infrastructure not only makes us extremely proud, it also could have an important strategic impact on our reference market. An EU blockchain infrastructure could represent the backbone on which EU Trust will be built in the future." He further commented: "InfoCert, as the leading Qualified Trust Service Provider in the EU, aims to further strengthen its thought leadership role in a constantly evolving market. InfoCert has an impressive track record in building innovative solutions and an ambitious R&D program focused on Digital Identity and Digital Trust. It includes the exploitation of emerging technologies, among which blockchain is one of the most promising. Our partners have tremendous technical competencies in distributed ledger technologies, while InfoCert has very distinctive expertise in building Trust Frameworks. Joining forces was natural and proved to be crucial in the success of our consortium."
About RIDDLE&CODE
RIDDLE&CODE is Europe's leading company for blockchain interface solutions. The company develops hardware and software stacks that combine the security of smart cards with blockchain and the Internet of Things (IoT). Together with its tier-one clients and partners, which include Daimler Mobility, BMW, Wien Energie and leading Dutch crypto exchange LiteBit, RIDDLE&CODE brings new business models to the fintech, energy, mobility and materials industries.
More information: www.riddleandcode.com
About Dyne.org
Dyne.org is a non-profit foundation dedicated to free and open source software and community development with 20 years of expertise in developing applications used worldwide. Its motto is "we are free to share code and we code to share freedom" and other projects include independent streaming software for free speech, privacy tools for activists and GNU/Linux distributions.
More information: dyne.org
About InfoCert
InfoCert, Tinexta Group, is the largest European Certification Authority, active in over twenty countries. The company provides services in digitisation, eDelivery, Digital Signature and digital preservation of documents and is an accredited AgID digital identity operator in the area of SPID (Public System for the management of Digital Identity). The company holds a 51% stake in Camerfirma, one of the principal Spanish certification authorities and a 16.7% stake in Authada, a leading-edge German Identity Provider.
More information: infocert.digital
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005128/en/
Contact information
Media contact for RIDDLE&CODE:
Aysenur Yükselal Aji
aysenur@riddleandcode.com
Media contact for Dyne.org
Andrea D'Intino
info@dyne.org
Media contact for InfoCert
comunicazioni@infocert.it
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom